Search Results

You are looking at 1 - 10 of 294 items for :

  • "threshold" x
  • All content x
Clear All
Full access

William J. Catalona and Stacy Loeb

increase to greater than 4 ng/mL within 4 years, in 1995 the authors reduced the PSA threshold for biopsy to 2.5 ng/mL, similar to the threshold of 3 ng/mL used in the European Randomized Study of Screening for Prostate Cancer (ERSPC). 4 From this study

Full access

Presenter: Natalie S. Callander

Smoldering multiple myeloma represents approximately 10% to 15% of all myeloma cases, but more thorough evaluation may decrease that number in the future. Risk stratification is important in this patient population to avoid overtreatment or undertreatment. Patients with low-risk disease can be observed without treatment, but those at higher-risk should be enrolled on clinical trials. If a clinical trial is not an option in these patients, a time-limited intervention with lenalidomide ± dexamethasone can be considered.

Full access

Daniel G. Coit and Anthony J. Olszanski

. Sentinel Node Biopsy “The panel has long struggled with defining thresholds for performing sentinel lymph node biopsy [SLNB] in patients with very thin melanomas,” said Dr. Coit. SLNB clearly provides important prognostic information and results in

Full access

Changyu Shen, Enrico G. Ferro, Huiping Xu, Daniel B. Kramer, Rushad Patell, and Dhruv S. Kazi

between 2008 and 2017 to (1) quantify the number of true-positive, false-positive, true-negative, and false-negative endpoints, and (2) determine whether alternative P value thresholds and/or sample size adjustments can improve the performance of phase

Full access

Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King, and Sasha Lupichuk

, survival effects of early (ie, anthracycline ± taxane) versus late (taxane only) dose reductions have not yet been fully characterized. This retrospective study investigated the effect of chemotherapy total cumulative dose (TCD) using historical thresholds

Full access

Naomi R.M. Schwartz, Lynn M. Matrisian, Eva E. Shrader, Ziding Feng, Suresh Chari, and Joshua A. Roth

: EDI, Early Detection Initiative; END-PAC, Enriching New-Onset Diabetes for Pancreatic Cancer; NOD, new-onset diabetes; PAC, pancreatic cancer; QALY, quality-adjusted life-year. Threshold Analysis Because the difference in the proportion

Full access

Celestia S. Higano

determined by a threshold value of serum PSA ( Figure 1 ). In either trial, if the PSA at the end of 8 months was greater than 4 ng/mL, patients were treated with continuous ADT. During the off-treatment interval, if the PSA increased to the threshold value

Full access

Lori L. DuBenske, Sarina B. Schrager, Terry A. Little, and Elizabeth S. Burnside

threshold of 80% agreement across all participants was set to establish consensus for retaining or dropping an item. In this study, separate stakeholder groups’ endorsement rates for each item were calculated. Items were deemed to have stakeholder

Full access

Sierra Cheng, Matthew C. Cheung, Di Maria Jiang, Erica McDonald, Vanessa S. Arciero, Doreen Anuli Ezeife, Amanda Rahmadian, Alexandra Chambers, Kelley-Anne Sabarre, Ambika Parmar, and Kelvin K.W. Chan

thresholds. Each bar exceeding this threshold (over or under) represents a HR OS–surrogate pair with substantial differences. Abbreviations: CBS, clinical benefit scores; HR OS, hazard ratio for death; HR PFS, hazard ratio for disease progression; mOS, median

Full access

Ranee Mehra, Candice Yong, Brian Seal, Marjolijn van Keep, Angie Raad, and Yiduo Zhang

cost-effectiveness ratio (ICER) of durvalumab, expressed as the cost per quality-adjusted life-year (QALY) gained for durvalumab following cCRT versus cCRT alone, using a $100,000 willingness-to-pay (WTP) threshold. Methods Patient Population Modeling